Skip to main content

AS/Spondyloarthritis

SpA,RNL,2022

RNL 2022: Spondyloarthritis Spectrum

May 18, 2022

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.



- Microbiome in Spondyloathritis - Jose Scher, MD



- Axial Psoriatic Arthritis - Philip Mease, MD



- Juvenile Spondyloathritis - Pamela Weiss, MD


Read Article
RheumNow Podcast square

Methotrexate Monitoring (5.13.2022)

May 13, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.




  1. Risk factors for readmission among 132,400 #SLE hospitalizatiions included

Read Article
Save the date! Join us on May 17th for Tuesday Night Rheumatology on Spondyloarthritis Spectrum. This webinar will feature lecture highlights followed by live audience Q & A.https://t.co/s7r09y5KNG https://t.co/0KYRPwGHsV
Dr. John Cush @RheumNow( View Tweet )
May 13, 2022
Diagnostic Delays in Spondyloarthritis Still Prolonged Previously quoted average delay in diagnosing axSpA may be improving as a recent UK study shows the mean average time to diagnosis in two different NHS trusts was between 5 and 6 years. https://t.co/6T9pck7nLa https://t.co/nwGBef2Gja
Dr. John Cush @RheumNow( View Tweet )
May 11, 2022
PsA,Pod,RNL

RNL 2022: Psoriatic Arthritis Advances

May 11, 2022

Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.



This webinar presented exerpts from these lectures along with audience Q & A



  • Psoriatic Arthritis Guidelines Arthur Kavanaugh, MD

  • Drug Targeting in PsA Bruce Kirkham
Read Article
Patient,instruction

Making You the Expert of You! (Smart Rules for Patients)

May 10, 2022

You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.

Read Article
SpA,AS,fusion

Diagnostic Delays in Spondyloarthritis Still Prolonged

May 09, 2022

Previously quoted average  delay in diagnosing axial spondyloarthritis (axSpA) may be improving as a recent UK study shows the mean average time to diagnosis in two different NHS trusts was between five and six years. 



The diagnostic delay in axSpA has been attributed to a slower

Read Article
RheumNow Podcast square

What is JAKne? (5.6.2022)

May 06, 2022

Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.




  1. Gout affects >10 million (4%) in USA, but now w/ more ethnicity, with highest risk in Native Hawaiians (HR 2.21), followed by Black (1.34) and Japanese (1.14);

Read Article
medical.marijuana

Lack of Research Stymies Uptake of Medical Marijuana for Rheumatic Pain

Creaky Joints
May 06, 2022

A new review article from CreakyJoints finds that there has been limited progress in understanding the potential of cannabis based therapies for the treatment of pain associated with rheumatic conditions in the past five years because of a lack of standardization of clinical research and

Read Article
There is 1.4 million transgender persons in the US. ACP has published a guideline "Care of the Transgender Patient" addressing health disparities, certain cancers, substance abuse, mental health conditions, infections, and chronic diseases. https://t.co/AoBeOzv9YH https://t.co/jKabVELPxH
Dr. John Cush @RheumNow( View Tweet )
May 06, 2022
Large Korean population study compares pts w/ palmoplantar psoriasis vs psoriasis and PPP pts have more risk for ankylosing spondylitis (aOR 1.37) & Graves dz (aOR 1.4) but lower risk for PsA (aOR 0.54), SLE (0.67); Sjögren (0.70); vitiligo (0.53) https://t.co/zrlvJpOhqc https://t.co/rxrEVHuUgm
Dr. John Cush @RheumNow( View Tweet )
May 06, 2022
Korean Health Insurance claims data looked at risk of Aortic Regurgitation, Atrial Fib in Axial Spondyloarthritis - 3:1 comparison of normals found axSpA (n 8877) at signif higher risk for aortic regurgitation (HR 2.55) & AF (1.20) https://t.co/BXLDymQDKZ https://t.co/YtUbwmKpkG
Dr. John Cush @RheumNow( View Tweet )
May 04, 2022
FDA%20approved.jpg (keep)

Upadacitinib FDA Approved for Ankylosing Spondylitis

May 02, 2022

Abbvie has announced the US Food and Drug Administration has approved upadacitinib (Rinvoq or UPA) for use in adults with active ankylosing spondylitis, who have not responded or been intolerant of one or more TNF blockers. The recommended dose is 15 mg per day.

Read Article
Today the FDA expanded the indications for upadacitinib (Rinvoq) to include ankylosing spondylitis - specifically for adults w/ active ankylosing spondylitis after failing a TNF blockers or other DMARDs. https://t.co/A9QhT98Djj

Dr. John Cush @RheumNow( View Tweet )

Apr 29, 2022
RheumNow Podcast square

$30 Billion and Counting (4.29.2022)

Apr 29, 2022

Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.

Read Article
SI,sacroiliitis,erosion

Prolonged TNF Inhibitor Use Delays Sacroiliac Progression

Apr 28, 2022

While tumour necrosis factor inhibitors (TNFi) have been shown to alter/retard X-ray outcomes in peripheral inflammatory arthritis, the inhibitor effects of TNFi on axial skeletal progression in spondylitis has been difficult to prove, owing to difficulties in study design, identifying best

Read Article
Spanish BIOBADASER registry real world performance of secukinumab in 639 pts w/ #PsA & spondyloarthritis (axSpA, AS, NR axSpA) showed imprved Dz activity at 1 yr & maintained or increased 2 & 3 years. Retention rates best when SEC used 1st biologic https://t.co/MAE3BhLlRg

Dr. John Cush @RheumNow( View Tweet )

Apr 26, 2022
COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients Putman et al has reported vaccine survey results from the C19-GRA in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD).https://t.co/sqsOHGThzV https://t.co/zeZrlDeQ9Z
Dr. John Cush @RheumNow( View Tweet )
Apr 25, 2022
ICYMI:Faith in Exercise Benefit Boosts Actual Benefit in SpA https://t.co/kEErN5IZUI https://t.co/9ve0ey9MRp
Dr. John Cush @RheumNow( View Tweet )
Apr 24, 2022
RheumNow Podcast square

Pre-exposure Prophylaxis for COVID-19 (4.22.22)

Apr 22, 2022

Dr. Jack Cush discusses the news and recent journal reports from last weeks RheumNow.com, and answers viewer questions from #ACA - Ask Cush Anything.

Read Article
vaccine,mRNA,Covid,vial

COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients

Apr 21, 2022

Putman et al has reported vaccine survey results from the COVID-19 Global Rheumatology Alliance (C19-GRA) in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD).

Survey data from 7005 vaccinated and unvaccinated, adult RMD respondents from 102

Read Article
TNR,controversies,psa

TNR - Controversies in PsA

Apr 20, 2022

Held on April 19, 2022, Tuesday Night Rheumatology: Controversies in PsA, featured a lively and informative panel discussion, moderated by Dr. Jack Cush.



The PsA Expert panelists included:



  • Dr. Dafna Gladman, Toronton

  • Dr. Joseph Merola, Boston

  • Dr. Peter
Read Article
exercise,group

Faith in Exercise Benefit Boosts Actual Benefit in SpA

MedPage Today
Apr 19, 2022

Patients with axial spondyloarthritis (SpA) got more bang for their exercise buck in a randomized trial when they had good opinions about their workout program, with better persistence with exercise at 1 year relative to a control group, researchers said.

Read Article
RheumNow Podcast square

Male vs. Female Responders (4.15.2022)

Apr 15, 2022

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 




  1. Downward Effects! Real world data from 22,934 UK #RA pts

Read Article
dementia,brain

Is Alzheimer's Risk Lower With TNF Inhibitors?

MedPage Today
Apr 11, 2022

Tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis were linked with a lower risk of Alzheimer's disease and related dementia, but only in people with cardiovascular disease, data from the DREAM (Drug Repurposing for Effective Alzheimer's Medicines) study showed.



Among

Read Article
×